Floatz logo

Hycamtin

Metastatic Pancreatic Cancer

National Cancer Institute (NCI)Phase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

71 Active assets in the Metastatic Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Calcium folinate pentahydrate
Jonsson Comprehensive Cancer Center
Phase 3BBB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Jonsson Comprehensive Cancer Center
Phase 2/3BB

View all 50 →

Same molecule, other indications

Hycamtin is also rated in:

primary peritoneal carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
non-small cell lung carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →